Compare Incyte Corporation (INCY) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs VanEck Rare Earth/Strategic Metals — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while VanEck Rare Earth/Strategic Metals trades at $60.99 (market cap $1.75B). The key difference: Incyte Corporation is far larger — about 13.1× VanEck Rare Earth/Strategic Metals's market cap, and Incyte Corporation is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| INCY | REMX | |
|---|---|---|
Market Cap | $22.85B | $1.75B |
Volume | 1,927,029 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $109.53 |
52-Week Low | $83.80 | $60.58 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $61.00, down 1.42% with a bearish technical signal. The ETF shows extreme oversold conditions with RSI readings near 14, while ADX indicates a strong downtrend. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, though individual holdings like Critical Metals show volatile performance. Bank of America increased its position by 72.1% in the latest quarter, holding 427,651 shares as of August 2026.
The outlook remains challenged by high volatility and China export controls, but strategic positioning for supply chain independence offers long-term potential. Investors face significant price swings with 50% annualized volatility, requiring risk tolerance. The bearish technical setup suggests caution near-term despite oversold conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
